Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Verhoogd risico op hart- en vaatziekten bij overlevenden van kanker
aug 2019 | Gynaecologische oncologie, Hoofd-halsoncologie, Longoncologie, Maag-darm-leveroncologie